In this commentary, Michael Bloch, MD, writes about the cardiovascular risk of exposure to ambient air pollution and how clinicians can play a role in mitigating exposure to reduce blood pressure and cardiovascular risk.
Commentary: Even Modest Reductions in Blood Pressure Can Lead to Substantial Reductions in Cardiovascular Events
In this article, Michael J. Bloch, MD, writes about studies over the past 30 years that prove lower achieved blood pressure, including modest reductions in blood pressure, translates to lower cardiovascular events.
In this Editorial, Editorial Board Member Michael J. Bloch, MD, reflects on a 1985 article from Consultant’s archives about how to properly use the laboratory to monitor drug therapy among patients with hypertension.
In this commentary, Michael Bloch, MD, writes about renin-angiotensin system-blocking agents and how they affect the disease course of COVID-19.
Will Renal Denervation Prove to Be a Viable Treatment Option for Blood Pressure That Is Treated but Not Controlled?
In this commentary, Michael J. Bloch, MD, writes about using nonpharmacological therapies, including endovascular renal denervation, to improve blood pressure control.
Rolando L. deGoma, MD, writes about how coronary calcium scores can impact patient care, especially when it comes to preventing heart disease and CVD events.
In this commentary, a team from Johns Hopkins Medicine writes about their experiences creating and implementing a digital health platform and explains how apps can contribute to improving patients’ health.
In this editorial by Consultant Board Member Dr Michael Bloch, he reflects on a 1961 Consultant article about cardiovascular disease management and how it has affected him.
In this commentary, Yehuda Handelsman, MD, deconstructs the common misconception that glucose control is the only important factor for managing diabetes and CVD.
Yehuda Handelsman, MD, writes about the importance of managing lipids in patients with diabetes and CVD, how hyperglycemia affects the body, and more.